Erin Fleming active positions
| Companies | Position | Start | End |
|---|---|---|---|
ProJenX, Inc.
 ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Chief Operating Officer | - | - |
| Chief Tech/Sci/R&D Officer | 31/12/2020 | - | |
| Founder | 31/12/2020 | - |
Career history of Erin Fleming
Statistics
International
| United States | 2 |
Operational
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Commercial Services |
- Stock Market
- Insiders
- Erin Fleming
- Experience
